Redeye comments on 2cureX’s TICC trial results which academic investigators published today. Patients receiving treatment based on IndiTreat results achieved 50% progression-free survival at two months, meeting and exceeding the primary endpoint of 40% PFS. This is a proof-of-concept for 2cureX’s vision of individualizing cancer treatment.